EGFR and non-small cell lung carcinoma: evaluation of the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV non-small cell lung cancer identified to carry an activating EGFR mutation and MET-positive